Viking Therapeutics (VKTX) Stock Price, Quote, News & History | Benzinga

Viking Therapeutics Inc (VKTX) Stock Price, Quote, News & History

VKTXNASDAQ

Trade with Public

Trade with Public

$33.19

0.250.76%

At close: Aug 14, 5:00 PM EST

$33.19

-0.00010%

After Hours: Aug 14, 7:51 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$32.56

Close

$33.19

Volume / Avg.

1.18M / 2.29M

Day Range

$32.33 - $33.28

52 Wk Range

22.96 - 43.15

Market Cap

$3.87B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

20.42%

Days to Cover

10.49

Recent Viking Therapeutics Inc News

Viking Therapeutics Stock Moves Lower: What's Going On?

Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected. Here's what you should know.

Evette Mitkov

Chip Rout Drags Nasdaq 100 Lower, Oil Climbs: Stock Market Today

A deepening chipmaker slide pulls all major U.S. indexes lower Tuesday while oil climbs on a Strait of Hormuz strike and defensive sectors led the tape.

Piero Cingari

Viking Advances New Amylin-Based Weight-Loss Drug Into Human Trials

Viking Therapeutics launches Phase 1 trial for obesity drug VK3019, a dual amylin/calcitonin receptor agonist. Read about the study.

Vandana Singh

Chip Bloodbath Hits Nasdaq 100 As South Korea Plunges: Stock Market Today

A global semiconductor sell-off hammered the Nasdaq on Tuesday, but a rotation into defensives and small caps kept the Dow green.

Piero Cingari

Stock Market Today: Oil Jumps 5%, S&P 500 Drops As Iran Strikes UAE Port

U.S. stocks sank Monday as an Iranian drone attack on a UAE petroleum site sent Brent above $114, gold tumbled 2%, and FedEx, UPS and GXO cratered after Amazon expanded its logistics business

Piero Cingari

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-418.44M

Investing Cash Flow (TTM)

399.26M

Financing Cash Flow (TTM)

111.25M

Free Cash Flow (TTM)

-418.44M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

92.06M

Analyst Trends and Forecast

1

Mar

1

Apr

2

May

1

Jul

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$3.37B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

9.41

Earnings Yield % (TTM)

-14.18%

Earnings Yield % (FWD)

-15.29%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.50

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$125.75M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$32.56

Close

$33.19

Volume / Avg.

1.18M / 2.29M

Day Range

$32.33 - $33.28

52 Wk Range

22.96 - 43.15

Market Cap

$3.87B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

44

Short Interest

20.42%

Days to Cover

10.49

About

Sector

Health Care

Industry

Biotechnology

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK021...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Viking Therapeutics (VKTX) stock?

A

You can purchase shares of Viking Therapeutics (NASDAQ:VKTX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Viking Therapeutics (VKTX) competitors?

A

Other companies in Viking Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Viking Therapeutics (VKTX) stock?

A

Viking Therapeutics has a consensus price target of $94.43.

Q

What is the current price for Viking Therapeutics (VKTX)?

A

The stock price for Viking Therapeutics (NASDAQ: VKTX) is $33.1899 last updated August 14, 2026 at 7:51 PM EDT.

Q

Does Viking Therapeutics (VKTX) pay a dividend?

A

There are no upcoming dividends for Viking Therapeutics.

Q

When is Viking Therapeutics (NASDAQ:VKTX) reporting earnings?

A

Viking Therapeutics does not have any upcoming earnings scheduled.

Q

Is Viking Therapeutics (VKTX) going to split?

A

There is no upcoming split for Viking Therapeutics.

Q

What sector and industry does Viking Therapeutics (VKTX) operate in?

A

Viking Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.